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Abstract
Introduction. The aim of our study was to characterize patients in Poland who buy in pharmacies over-the-counter for-
mulations of acetylsalicylic acid (ASA) in doses recommended by cardiologists as well as to attempt a risk stratification 
of this population.
Material and methods. We used standardized electronic questionnaires addressed to patients coming to pharmacies. 
Patients were interviewed by pharmacists or pharmacy technicians.
Results. The survey included 532 patients who bought ASA drug for themselves. Most of them have not previously had 
any cardiovascular events, and the decision to start ASA was the result of a medical professional’s recommendation. 
The percentage of people who were motivated by mass media advertising was much smaller, at approximately 20%.
Conclusions. It is suggested that the most important indications for use of ASA in cardiologic doses are those concer-
ning primary prevention. This observation warrants performing further diagnostic work-up, and points out to the role of 
physicians and pharmacists in therapy monitoring.
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Introduction
Identification of new, molecularly defined targets of ace-
tylsalicylic acid (ASA) as well as recent population studies 
contributed resulted in shifting the drug from antipyretic 
and analgesic category to cardiologic agents. Acetylsalicylic 
acid causes non-selective blockage of cyclooxygenase (COX), 
thereby decreasing synthesis of tissue prostaglandins inclu-
ding prostacyclin (PGI2), which is one of the key players of 
the inflammatory reaction. The agent inhibits also synthesis 
of thromboxane A2 (TXA2), the molecule which stimulates 
platelet aggregation and is a potent vasoconstrictor [1, 2]. 
This mechanism is of major importance when considering 
complications of ischemic heart disease. Deposition of 
platelet aggregates on atherosclerotic plaques may lead 
to thrombosis, which in turn may decrease myocardial per-
fusion. Enzyme inhibition by ASA is irreversible, and lasts 
until a whole new population of thrombocytes is generated, 
which takes approx. 7–10 days. Thereafter physiological 
generation of inflammatory markers is reinstituted [3].
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Administration of low ASA doses (i.e. between 30 mg 
and 150 mg) is supported by results of pharmacological 
studies and numerous clinical trials. These studies aimed 
to investigate the balance between TXA2 action in platelets 
and PGI2 effect on endothelial cells. At the same time, the 
studies were intended to verify the antiplatelet effect of 
ASA at the lowest possible therapeutic dose. The proper 
selection of ASA dosage permits inhibition of platelet 
cyclooxygenase, with a low risk of side effects, retained 
possibility of combining ASA with other antiplatelet agents 
but also may define indications for treatment [3]. It is sug-
gested that ASA can play a major role in primary prevention, 
although its effects are mainly appreciated in secondary 
prevention (e.g. in patients who had a myocardial infarct), 
irrespective of the applied modality of patency restoration 
in the occluded coronary artery [4–8].
Despite widespread availability and increased interest 
in ASA effects expressed by physicians, pharmacists and 
patients, the population of patients taking ASA in cardio-
logic doses is not completely characterized, mainly due to 
lack of prescription requirement. It can be assumed that 
not only consultation by a physician or pharmacist but also 
a mass media play an important role in decision making, 
resulting in increased patient self-medication. Furthermore, 
there is no complete data concerning the most common 
indication for ASA therapy. Available data does not spe-
cify how many of the ASA taking subjects have actually 
undergone cardiovascular events or how many persons 
take ASA as means of primary prevention, indications for 
which are currently being restricted. Irrespective of patient 
classification (primary vs. secondary prevention), it is also 
of importance to evaluate the amount of patients on ASA 
therapy who undergo coagulation tests and/or peripheral 
blood status analysis, especially when this agent is admini-
stered together with other antiplatelet and/or anticoagulant 
drugs. These parameters may be of value in assessment of 
potential benefits and limitations of introducing antiplatelet 
therapy in a given patient, which in turn can optimize the 
whole treatment.
The aim of this study was to characterize patients 
buying ASA in pharmacies in Poland as well an attempt to 
risk-stratify this population.
Material and methods
The study was performed using a standardized question-
naire presented to pharmacy customers who bought ASA 
in cardiologic doses. Digital questionnaire consisted of 
15 closed-ended questions, and was a part of software 
developed and owned by the Infomed Sp. z o.o. compa-
ny, installed in 100 pharmacies throughout Poland. The 
interviews were performed by pharmacists and pharmacy 
technicians. Consent to study participation by the patient 
as well as agreement to fill in the questionnaire by the phar-
macy personnel were voluntary, with clause of anonymity 
respected. Study protocol and questionnaire were approved 
by the Bioethical Committee of the Medical University of 
Warsaw. The study duration was 2 months. Table 1 contains 
all the questions included in the study questionnaire.
Results
The study included 780 persons, and the target group con-
sisted of persons buying ASA for themselves (532 persons, 
68.21%). In this population there was predominance of 
women (296 persons, 55.64%). Mean age of the intervie-
wed person was 62 years. Most interviewees did not have 
a higher education (212 persons, 39.8%), although many 
(232 persons, 43.61%) refused answering this question.
Vast majority of interviewees bought ASA for a con-
secutive time (436 persons, 81.95%), having previously 
read the accompanying leaflet (332 persons, 76.15%, 
Fig. 1). The study revealed that among all the available 
ASA formulations in recommended cardiologic doses, the 
most often bought one was that of 75 mg (428 persons, 
80.45%, Fig. 2). The doses that were chosen less often 
were 150 and 100 mg (68 and 36 persons, 12.78% and 
6.77% respectively). None of the interviewees bought ASA 
in the registered dose of 30, 50 or 325 mg.
When asked about the previous cardiovascular events 
(cardiac infarct and/or stroke, Fig. 3), almost 56% of the 
study subjects (296 persons) reported never having such 
an episode. That would mean that ASA treatment in the 
population of interest was aimed at primary prevention. 
Table 1. Questions from the digital patient questionnaire
Did you but the medication for yourself/for someone else?
Did you buy it for the first time/a consecutive time?
Did you read the drug leaflet?
If buying the drug again: did you buy this it in the same  
pharmacy as previously/at another pharmacy?
Do you buy the drug: after having seen a media commercial/ 
/following someone’s recommendation/having a prescription 
form a physician/for another reason?
Where did you encounter media commercial for the drug?
Who recommended the drug to you?
What is your sex?
What is your year of birth?
Do you have secondary education?
You bought the drug at which dose?
Have you had a cardiac infarct?
Have you had a stroke?
Have you had a cardiac infarct and a stroke? 
Do you check your coagulation parameters and/or  
blood status?
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The results may possibly apply to all persons who take ASA 
containing formulations.
Most interviewees decided to buy ASA following re-
commendation of a medical professional (376 persons, 
70.68%). There were far fewer persons responding to me-
dia commercials (19.55%, 104 persons). When asked for 
sources of recommendation, most persons named having 
received a written information on ASA from a physician 
during medical appointment (200 persons, 53.19%, Fig. 4). 
Further 84 persons (22.34%) received prescription for ASA. 
Ordination by a pharmacist was named by 56 persons 
(14.89%). Media channel that was most often named by 
the interviewees was TV and commercials shown therein 
(76 persons, 73.08%, Fig. 5), followed by radio (16 persons, 
15.38%), and press and internet advertisements (8 and 
4 persons respectively, 7.69% and 3.85%).
Discussion
Current recommendations for ASA therapy in cardiology 
include a broad spectrum of diseases, including unstab-
Figure 1. Interviewees’ answers to the question “Did you read the 
drug leaflet?”
Figure 2. Doses of acetylsalicylic acid (ASA) chosen by the persons 
buying the drug
Figure 3. Interviewees’ answers to the question concerning past 
cardiovascular events
Figure 4. Interviewees answers to the question about recommen-
dation to start ASA therapy
Figure 5. Interviewees’ answers to the question concerning the 
source of commercial information on the drug; TV — televison
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le angina pectoris, secondary prophylaxis of cardiac 
infarcts and stroke as well as follow-up therapy after 
revascularization procedures but ASA is currently of no 
importance in prophylaxis of thromboembolic disease [9]. 
Acetylsalicylic acid is commonly recommended in patients 
with coronary heart disease and diseases of peripheral 
vessels, in which antiplatelet agents are one of the ma-
instays of therapy, alongside with lifestyle modifications 
and evaluation of risk factors [10]. Relatively low cost of 
treatment, and significant and well-documented effects 
of antiplatelet agents in secondary prevention led to ex-
trapolation of low dose ASA-protocols (of 35 to 150 mg) 
to primary prevention of various diseases. These findings 
were reflected in guideline documents of national and 
international specialist associations (American Heart 
Association, American Diabetes Association, American 
College of Cardiology) but, at the same time, were never 
unequivocally supported by the published data, and thus 
became much more restricted by the European associa-
tions (European Society of Cardiology, Polish Society of 
Cardiology) [11–15]. Current opinion of Food and Drug 
Administration (FDA) is in line with this restrictive appro-
ach, as the agency does not recommend routine low dose 
ASA therapy in patients who have not previously had any 
cardiovascular episodes. This is due to lack of definitive 
proof of ASA efficacy in primary prophylaxis and due to 
risk of hemorrhagic complications [16].
All ASA-containing formulations with cardiologic doses 
are registered in Poland as over the counter drugs (OTC). 
Many such formulations are commercially available but lite-
rature on the subject does not give a uniform or systematic 
insight into reasons for which Polish patients get these 
drugs. The presented survey clearly suggests that indica-
tions related to primary prophylaxis may be more important 
in this patient population than secondary prophylactic 
measures. This can be implied from the fact that many 
patients choose the ASA dose of 75 mg but also from the 
observation that relatively many ASA consumers have not 
previously had any cardiovascular episodes. These results 
may be in accordance with guidelines from most scientific 
societies, and comply with registered indications for use 
but are not reflecting the most recent scientific data. What 
should be noted, the role of ASA in primary prevention re-
mains controversial, and requires individual risk and benefit 
assessment for each patient. Results presented herein, 
suggesting emphasis on primary prevention, can therefore 
raise questions as to the necessity of the ASA purchase by 
a certain number of interviewed persons [4, 17].
Moreover, the study emphasizes the need of regular 
follow-up of patients treated with acetylsalicylic acid. In 
the studied population, almost 40% persons admitted 
never having their blood status or coagulation parameters 
controlled (Fig. 6).
These findings point out to the role of patient education, 
not only during medical appointments but also in pharma-
cies. The latter aspects may reflect the role of professional 
pharmaceutical service, where standardized electronic 
questionnaires facilitate optimization of patient interview, 
and thus permit achieving a greater control over safety and 
efficacy of pharmacological therapy.
Such tolls may present sources of recommendations, 
and permit verification of mass media communications 
concerning medical substances, which are not prescribed 
by physicians but still are commonly and aggressively adver-
tised. Acetylsalicylic acid in cardiologic doses is classified 
as OTC, however the most important source of recommen-
dations for therapy remains a physician. Presented study 
revealed that over 75% of all interviewees consulted ASA 
purchase with a physician, whereas only 15% were advised 
by a pharmacist. This does not mean that the qualified 
pharmacy personnel should be deprived of the capabilities 
of controlling ongoing pharmacological therapy. Pharma-
cists are the last instance in medical prescription chain, 
and are the only professional group that has access to all 
the patient’s prescriptions pending under a period of time. 
This permits taking active steps to prevent potential drug 
interactions or potentially negative dose doubling of a single 
active substance, e.g. when ASA is prescribed by different 
specialists or under different commercial names (brands). 
It is estimated that introduction of the pharmaceutical care 
system, including electronic questionnaires and patient files 
with current laboratory test results, may enrich pharmacists’ 
competence and permit optimization of ASA therapy.
Physician-pharmacist cooperation as to ordination 
of anticoagulant agents may decrease potential adverse 
effects of patient self-medication. Patient’s choices as 
to pharmacological therapy may be heavily influenced by 
Figure 6. Interviewees’ answers to the question concerning pe-
ripheral blood and/or coagulation parameters testing
162
Folia Cardiologica 2015, tom 10, nr 3
www.fc.viamedica.pl
advertising campaigns in mass media. Most persons inter-
viewed during the presented study declared recommenda-
tion from a physician as the motive for their purchase of 
ASA, however a certain percentage (20%) declared being 
influenced by commercial advertising materials, which 
cannot be underestimated. The latter group should there-
fore be more actively taken care of by physicians, as these 
persons may not have access to the complete information 
on therapeutic purpose and safety of ASA therapy. Besides, 
patients influenced by advertisements when deciding to 
buy ASA never consult a physician first. This puts a grea-
ter responsibility on pharmacists, and warrants including 
a question concerning drug advertising, as in the presented 
study questionnaire. Such an interview may reflect on the 
necessity of ASA therapy but also result in advising patient 
to consult a physician and/or perform laboratory tests.
Conclusions
1. Indications for ASA therapy as means of primary prophy-
laxis of cardiovascular episodes were more commonly 
reported as compared to secondary prophylaxis.
2. Dominance of primary prevention-related indications 
makes the necessity of ASA treatment in the presented 
group highly debatable.
3. This finding warrants advising regular laboratory tests 
in the presented group.
4. Acetylsalicylic acid formulations are classified as over-
-the-counter drugs, however physician remains the main 
source of recommendations in this regard.
5. Standardized electronic questionnaires for patients as 
a part of professional pharmaceutical care system may 
be an useful educational tool, permit control of patient’s 
laboratory test results and monitoring safety of OTC 
therapy, including administration of ASA in cardiologic 
doses.
6. Physician-pharmacist cooperation as to ordination of 
anticoagulant agents may decrease potential adver-
se effects of patient self-medication, stimulated by 
aggressive mass media advertising campaigns.
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Streszczenie
Wstęp. Celem badania była charakterystyka pacjentów nabywających w ogólnodostępnych aptekach preparaty kwasu 
acetylosalicylowego (ASA) rekomendowanego w dawkach kardiologicznych, a także jej powiązanie z próbą stratyfikacji 
grup ryzyka tych osób.
Materiał i metody. Wykorzystano wystandaryzowane ankiety w formie elektronicznej skierowane do pacjentów zgłasza-
jących się do aptek. Wywiad przeprowadzali farmaceuci lub technicy farmaceutyczni.
Wyniki. Badanie objęło 532 pacjentów, którzy kupili preparat ASA dla siebie. Większość z nich nie przybyła wcześniej 
incydentów sercowo-naczyniowych, zaś decyzja o rozpoczęciu leczenia stanowiła wynik rekomendacji profesjonalisty 
medycznego. Odsetek osób, które kierowały się reklamą mediach, był znacznie mniejszy i kształtował się na poziomie 
około 20%.
Wnioski. Sugeruje się, że w kontekście stosowania preparatów ASA w dawkach kardiologicznych największe znaczenie 
nadal mają wskazania objęte profilaktyką pierwotną. Obserwacja ta implikuje konieczność wykonywania dodatkowych 
badań diagnostycznych w tej grupie pacjentów, jak również wskazuje na rolę lekarzy i farmaceutów w procesie monito-
rowania farmakoterapii.
Słowa kluczowe: kwas acetylosalicylowy, badanie ankietowe, prewencja pierwotna, prewencja wtórna
(Folia Cardiologica 2015; 10, 3: 158–163)
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Wprowadzony na rynek farmaceutyczny w 1899 roku kwas acetylosalicylowy (ASA, 
acetylsalicylic acid) jest obecnie jednym z najczęściej stosowanych leków na świecie. 
Popularność ASA zwiększała się stopniowo w pierwszej połowie XX wieku, między innymi 
za sprawą znacznej skuteczności leku w trakcie pandemii grypy „hiszpanki” w 1918 roku. 
Popularność ta nieco zmalała po wprowadzeniu na rynek paracetamolu (1956 r.) oraz 
ibuprofenu (1969 r.), jednak liczne badania kliniczne, prowadzone w latach 80. i 90. 
XX wieku, ugruntowały ostatecznie nową, kolejną wartość ASA jako środka hamujące-
go agregację płytek krwi, sankcjonując jego istotne miejsce w terapii chorób układu 
sercowo-naczyniowego (CV, cardiovascular) [1]. Kwas acetylosalicylowy odgrywa obecnie niepodważalną rolę jedynie 
w prewencji wtórnej epizodów CV, ponieważ jego zastosowanie w prewencji pierwotnej jest znacznie słabiej udokumen-
towane i stanowi przedmiot wielu kontrowersji i dyskusji [2–5]. Przedefiniowanie roli i znaczenia tego leku w profilakty-
ce pierwotnej wynikało przede wszystkim z wąskiej granicy między korzyścią związaną ze stosowaniem ASA a ryzykiem 
powikłań krwotocznych. Decyzja dotycząca zastosowania ASA w prewencji pierwotnej bywa coraz trudniejsza, a jego 
zastosowanie w tym wskazaniu powinno być starannie wyważone. Grupa Robocza ds. Zakrzepicy Europejskiego Towa-
rzystwa Kardiologicznego (Working Group on Thrombosis of European Society of Cardiology) jedynie sugeruje zasto-
sowanie ASA w prewencji pierwotnej u tych chorych, u których ryzyko incydentu CV (zawału serca, udaru mózgu, zgonu 
z przyczyn CV) w perspektywie 10-letniej wynosi nie mniej niż 20%, co odpowiada 7–10-procentowemu ryzyku w skali 
EuroSCORE (European System for Cardiac Operative Risk Evaluation) [6]. Potwierdzeniem takiego stanu rzeczy może 
być również ostatnie stanowisko amerykańskiej Agencji ds. Żywności i Leków (FDA, Food and Drug Administration), któ-
ra nie zaleca rutynowego stosowania ASA u chorych, którzy nie przebyli wcześniej epizodów sercowo-naczyniowych [7].
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nabywających w aptekach ASA w rekomendowanych dawkach kardiologicznych. Szczegółowa analiza badania wyka-
zała, że najczęściej stosowaną dawką ASA jest 75 mg. Niepokoi fakt, że aż 56% ankietowanych osób przyjmowało 
ten lek w prewencji pierwotnej, w której stosowanie go (jak wyżej podkreślono) jest obecnie kontrowersyjne i wymaga 
indywidualnego oszacowania potencjalnych korzyści i działań niepożądanych. Cieszy sytuacja, że prawie 71% ankieto-
wanych kupiło leki w wyniku rekomendacji profesjonalisty medycznego, a jedynie 20% kierowało się reklamą w środ-
kach masowego przekazu. Wyniki przedstawione w opracowaniu wyraźnie sugerują, że wskazania do stosowania ASA 
w zakresie profilaktyki pierwotnej mogą przewyższać te charakterystyczne dla prewencji wtórnej, co może rodzić wiele 
pytań i wątpliwości dotyczących zasadności stosowania ASA u części nabywających je osób. Bardzo dobrym pomysłem 
zasugerowanym przez autorów artykułu jest propozycja wprowadzenia modelu opieki farmaceutycznej opartej na wy-
korzystaniu elektronicznych kwestionariuszy i kart pacjenta, co może wpłynąć na szybkie wdrożenie działań prewencyj-
nych wobec potencjalnych interakcji lekowych lub negatywnego dublowania tej samej substancji czynnej ordynowanej 
przez kilku lekarzy. Farmaceuta może pełnić również niezwykle istotną rolę w zalecaniu ASA, ograniczając negatywne 
konsekwencje powszechnego „samoleczenia” związanego głównie z nachalną reklamą. Przedstawiony artykuł stanowi 
bardzo ważny „głos” dotyczący stosowania ASA przez polskich pacjentów, wnosząc wiele istotnych informacji, które 
powinny mieć w przyszłości przełożenie na codzienną praktykę kliniczną.
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